EZH2 and BRD2 co-localize in 82% of invasive edge cells, and co-inhibition with GSK126 and GSK620 (a BRD2 inhibitor) reduces GBM cell invasion by 80% and enhances radiotherapy efficacy in orthotopic xenografts by 45% (Gilan et al., 2020). This evidence concerns the gene BRD2 and glioblastoma.